17.09.20: ESMO Virtual Congress 2020:

New data reinforce strong clinical profile of Vitrakvi™ for patients of all ages with TRK Fusion Cancer including lung and thyroid tumors78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children / Majority of adverse events were grade 1 or 2; no new safety signals identified / Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively) as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) / Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7)mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news